pharmaphorum July 30, 2024
Boehringer Ingelheim has bought Nerio Therapeutics, saying that it is adding a programme that – while still in preclinical development – could be a “centrepiece” of its immuno-oncology pipeline.
California, US-based Nerio is developing a series of small-molecule checkpoint inhibitors designed to rev up the immune system to fight cancers, focusing on compounds that target protein tyrosine phosphatases N1 and N2 (PTPN1 and PTPN2).
According to Nerio, inhibiting these enzymes can disrupt a tumour’s ability to evade the immune system and, according to co-founder and chief executive Sanford Madigan – also a partner at Avalon BioVentures, which incubated Nerio since its founding in 2019 – its compounds have “superior drug-like properties and provide a first-in-class opportunity.”
The biotech has been...
Today's Sponsors
Today's Sponsor